{"id":110445,"date":"2021-03-24T17:47:31","date_gmt":"2021-03-24T17:47:31","guid":{"rendered":"https:\/\/fin2me.com\/?p=110445"},"modified":"2021-03-24T17:47:31","modified_gmt":"2021-03-24T17:47:31","slug":"covid-19-vaccine-astrazeneca-roller-coaster-ride","status":"publish","type":"post","link":"https:\/\/fin2me.com\/markets\/covid-19-vaccine-astrazeneca-roller-coaster-ride\/","title":{"rendered":"COVID-19 vaccine AstraZeneca roller-coaster ride"},"content":{"rendered":"
(Reuters) – AstraZeneca is due to publish up-to-date results from its major U.S. COVID-19 vaccine trial, after health officials publicly criticized it for using \u201coutdated information\u201d to show how well the immunization worked.<\/p> Here\u2019s a look at the progress of the vaccine development to date since its inception.<\/p>\n A team involving Oxford Vaccine Group and Jenner Institute starts work on developing a vaccine to prevent COVID-19.<\/p>\n Researchers at the Oxford University begin screening healthy volunteers, aged 18-55, for recruitment in the ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region.<\/p>\n Human trials begin<\/p>\n AstraZeneca and Oxford join forces for development and potential large scale distribution of the vaccine candidate.<\/p>\n AstraZeneca and Oxford start recruiting volunteers for a much larger human trial in the UK.<\/p>\n Initial safety data released showed vaccine was safe and produced an immune response.<\/p>\n Vaccine candidate begins late-stage study in the United States.<\/p>\n AstraZeneca suspends global trials due to an unexplained illness in a study participant.<\/p>\n AstraZeneca resumes UK trials.<\/p>\n Oxford\/AstraZeneca begin submitting data to the UK regulator under a rolling review process.<\/p>\n EU launches real-time review of the vaccine.<\/p>\n United States restarts trial, the last one to do so after other regions began resumption much earlier.<\/p>\n AstraZeneca confirms that the UK regulator has started an accelerated review of vaccine.<\/p>\n Interim late-stage data from UK, South Africa trials released:<\/p>\n The vaccine on average prevented 70% of COVID-19 cases in late-stage trials in Britain and Brazil.<\/p>\n The success rate rose to 90% in a group of trial participants who accidentally received a half dose followed by a full dose.<\/p>\n The efficacy was 62% if the full dose was given twice, as it was for most study participants.<\/p>\n Britain approves shot in first for COVID-19 vaccines in the West. Regulators said that the higher efficacy seen in the half-dose\/full-dose cohort was likely a result of a longer gap between doses, rather than the amount of vaccine given.<\/p>\n India approves Serum\u2019s vaccine days later in early January.<\/p>\n Europe gives vaccine green light in late January.<\/p>\n The World Health Organisation gives the vaccine a go-ahead.<\/p>\n AstraZeneca cut its first-quarter supply forecast to the EU due to export constraints.<\/p>\n Austria halts use of one batch of vaccine following reports of cases of blood clots in Nordic countries.<\/p>\n More than a dozen European countries, including Germany and France, followed suit and halted use of the vaccine.<\/p>\n European regulators and WHO back vaccine\u2019s safety in mid-March.<\/p>\n In late March, interim data from late-stage trials in U.S., Peru, Chile shows vaccine is 79% effective.<\/p>\n The U.S. National Institute of Allergy and Infectious Diseases said the drugmaker may have included outdated information from the trial, providing an incomplete view of the efficacy data.<\/p>\nJANUARY 2020:<\/h2>\n
MARCH 2020:<\/h2>\n
APRIL 2020:<\/h2>\n
MAY 2020:<\/h2>\n
JULY 2020:<\/h2>\n
AUGUST 2020:<\/h2>\n
SEPTEMBER 2020:<\/h2>\n
OCTOBER 2020:<\/h2>\n
NOVEMBER 2020:<\/h2>\n
DECEMBER 2020:<\/h2>\n
JANUARY 2021:<\/h2>\n
FEBRUARY 2021:<\/h2>\n
MARCH 2021:<\/h2>\n